KSP 1007
Alternative Names: KSP-1007Latest Information Update: 28 Mar 2025
At a glance
- Originator Kitasato Institute; Sumitomo Dainippon Pharma
- Developer Kitasato Institute; Sumitomo Pharma; Sumitomo Pharma America
- Class Anti-infectives; Antibacterials; Urinary anti-infective agents
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
- No development reported Bacterial infections
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Intra-abdominal-infections in USA
- 28 Mar 2025 No recent reports of development identified for phase-I development in Urinary-tract-infections in USA
- 28 Feb 2025 No recent reports of development identified for phase-I development in Bacterial-infections(Combination therapy, In volunteers) in USA (IV)